Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome

Acadia Pharma (ACAD) Tops Q3 EPS by 11c

October 30, 2019 4:27 PM EDT

Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.29), $0.11 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $94.6 million versus the consensus estimate of $88.49 million.

We took a major step forward in fulfilling our mission to improve the lives of... More